- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05900141
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (OLE)
A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Berlin, Germany, 13353
- Recruiting
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Recruiting
- Novartis Investigative Site
-
Mainz, Germany, 55131
- Recruiting
- Novartis Investigative Site
-
Muenchen, Germany, 81377
- Recruiting
- Novartis Investigative Site
-
Wuerzburg, Germany, 97080
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent
- Participant has successfully completed the parent study and is considered safe to participate by Investigator's clinical judgement.
Exclusion Criteria:
- Any medical condition(s) that may put the participant at risk in the investigator's opinion
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, unless they are using effective methods of contraception during dosing and for 16 weeks (= 5 times the terminal half-life) after stopping of study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pelacarsen (TQJ230)
open-label pelacarsen 80 mg
|
Pelacarsen 80mg s.c. monthly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse events (AEs) or serious adverse events (SAEs), including changes in laboratory evaluations, vital signs qualifying and reported as AEs.
Time Frame: 60 months
|
Evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants with elevated Lp(a) and established cardiovascular disease who have competed the parent study
|
60 months
|
Duration of drug exposure
Time Frame: 60 months
|
Duration of drug exposure will be collected
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of lipoprotein apheresis sessions performed yearly for year 1, 2, 3, 4 and 5
Time Frame: 60 months
|
Evaluate the long-term effect of pelacarsen on the need for lipoprotein apheresis.
|
60 months
|
Absolute change in Lp(a) compared to baseline of the parent study.
Time Frame: month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)
|
Evaluate the long-term effect of pelacarsen on Lp(a) change.
|
month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)
|
Percentage change in Lp(a) compared to baseline of the parent study.
Time Frame: month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)
|
Evaluate the long-term effect of pelacarsen on Lp(a) change.
|
month 1, month 3, month 6, month 9, month 12, then every 6 months during OLE (up to 60 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTQJ230A12302E1
- 2023-503611-16-00 (Registry Identifier: EUCTR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipoproteinemia (a)
-
Novartis PharmaceuticalsActive, not recruiting
-
Technische Universität DresdenKaneka Pharma Europe N.V.RecruitingLipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaGermany
-
Changi General HospitalNot yet recruitingCardiovascular Diseases | Hypercholesterolemia | Lipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaSingapore
-
Charite University, Berlin, GermanyWithdrawnHyperlipoproteinemia(a) | Progressive Cardiovascular DiseaseGermany
-
Fresenius Medical Care Deutschland GmbHCompletedHypercholesterolemia, Familial | LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIAGermany
-
Akcea TherapeuticsIonis Pharmaceuticals, Inc.CompletedCardiovascular Disease | Elevated Lipoprotein(a)United States, Canada, Denmark, Germany, Netherlands
-
AstraZenecaCompletedHypertriglyceridemia | Hyperlipidemia | Hyperlipoproteinemia Type V | Hyperlipoproteinemia Type IV | Hyperlipoproteinemia Type IIbMexico
-
Nina HermansUniversity Hospital, AntwerpRecruitingLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaBelgium
-
S.LAB (SOLOWAYS)Center of New Medical Technologies; Triangel ScientificCompletedLDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II DiseaseRussian Federation
-
Hospices Civils de LyonCompleted
Clinical Trials on Pelacarsen
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsNot yet recruitingElevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
-
University Medical Centre LjubljanaWithdrawnInflammation | Acute Coronary Syndrome | Lipoproteinemia | Genetic PolymorphismsSlovenia
-
Novartis PharmaceuticalsRecruitingAortic StenosisIsrael, United States, Canada, United Kingdom
-
Ionis Pharmaceuticals, Inc.CompletedHealthy ParticipantsUnited States
-
Novartis PharmaceuticalsActive, not recruiting
-
Akcea TherapeuticsIonis Pharmaceuticals, Inc.CompletedCardiovascular Disease | Elevated Lipoprotein(a)United States, Canada, Denmark, Germany, Netherlands